Ulipristal and Other Medical Interventions for Treatment of Uterine Fibroids

doi:10.1017/9781108332798.004

Chapter 3 - Ulipristal and Other Medical Interventions for Treatment of Uterine Fibroids

Published online by Cambridge University Press: 10 October 2020

Mohamed Ali ,

Zunir Tayyeb Chaudhry and

Ayman Al-Hendy

Edited by

Mostafa Metwally and

Tin-Chiu Li

Show author details

Mostafa Metwally: Affiliation:
University of Sheffield
Tin-Chiu Li: Affiliation:
The Chinese University of Hong Kong

Book contents

Get access

Summary

Uterine fibroids (UFs) are the most common non-malignant neoplasms affecting women of reproductive age. Some estimates suspect nearly 70–80% of all women will develop at least one fibroid during their lifetime [1]. Women suffering from UFs can present with heavy or prolonged vaginal bleeding, pain or pressure in pelvic region, dysmenorrhoea, dyspareunia, bladder problems, constipation, subfertility, and even loss of pregnancy [2]. Many women with fibroids experience heavy menstrual bleeding (HMB), thereby making them more prone to developing iron deficiency anaemia [3]. Many women suffering from severe symptomatic fibroids choose to have a hysterectomy, making it the second most commonly performed procedure in the United States [4]. Unfortunately the risks involved with surgery, in conjunction with the possibility of eradicating any hope of future pregnancies, make it a less favourable option for women. Thus understanding the pathogenesis behind fibroid formation is paramount for the development of novel therapeutic strategies.

Type: Chapter
Information: Modern Management of Uterine Fibroids , pp. 22 - 27

DOI: https://doi.org/10.1017/9781108332798.004 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Baird, DD, Dunson, DB, Hill, MC, Cousins, D, Schectman, JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003;188(1):100–7.Google Scholar

Stewart, EA. Uterine fibroids. Nat Rev Dis Primers 2016;2:16043.Google Scholar

Pritts, EA, Parker, WH, Olive, DL. Fibroids and infertility: an updated systematic review of the evidence. Fertil Steril 2009;91(4):1215–23.Google Scholar

Cardozo, ER, Clark, AD, Banks, NK, et al. The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol 2012;206(3):211.e1–9.Google Scholar

Bulun, SE. Uterine fibroids. N Engl J Med 2013;369(14):1344–55.Google Scholar

Borahay, MA, Asoglu, MR, Mas, A, et al. Estrogen receptors and signaling in fibroids: role in pathobiology and therapeutic implications. Reprod Sci 2017;24(9):1235–44.Google Scholar

Ciavattini, A, Di Giuseppe, J, Stortoni, P, et al. Uterine fibroids: pathogenesis and interactions with endometrium and endomyometrial junction. Obstet Gynecol Int 2013;2013:173184.Google Scholar

Lusher, SJ, Raaijmakers, HC, Vu-Pham, D, et al. Structural basis for agonism and antagonism for a set of chemically related progesterone receptor modulators. J Biol Chem 2011;286(40):35079–86.CrossRef Google Scholar PubMed

Bouchard, P. Selective progesterone receptor modulators: a class with multiple actions and applications in reproductive endocrinology, and gynecology. Gynecol Endocrinol 2014;30(10):683–4.CrossRef Google Scholar

Wagenfeld, A, Saunders, PT, Whitaker, L, Critchley, HO. Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies. Expert Opin Ther Targets 2016;20(9):1045–54.Google Scholar

Donnez, J, Donnez, O, Dolmans, MM. The current place of medical therapy in uterine fibroid management. Best Pract Res Clin Obstet Gynaecol 2017.Google Scholar

Reis, FM, Bloise, E, Ortiga-Carvalho, TM. Hormones and pathogenesis of uterine fibroids. Best Pract Res Clin Obstet Gynaecol 2016;34:13–24.Google Scholar

Ali, M, Al-Hendy, A. Selective progesterone receptor modulators for fertility preservation in women with symptomatic uterine fibroids. Biol Reprod 2017;97(3):337–52.Google Scholar

Donnez, J, Tomaszewski, J, Vázquez, F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012;366(5):421–32.Google Scholar

Donnez, J, Donnez, O, Courtoy, GE, Dolmans, MM. The place of selective progesterone receptor modulators in myoma therapy. Minerva Ginecol 2016;68(3):313–20.Google Scholar PubMed

Yoshida, S, Ohara, N, Xu, Q, et al. Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. Semin Reprod Med 2010;28(3):260–73.Google Scholar

Xu, Q, Ohara, N, Liu, J, et al. Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. Mol Hum Reprod 2008;14(3):181–91.CrossRef Google Scholar PubMed

Courtoy, GE, Donnez, J, Marbaix, E, Dolmans, MM. In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment. Fertil Steril 2015;104(2):426–34.e1.Google Scholar

Murji, A, Whitaker, L, Chow, TL, Sobel, ML. Selective progesterone receptor modulators (SPRMs) for uterine fibroids. Cochrane Database Syst Rev 2017;4:CD010770.Google Scholar

Donnez, J, Tatarchuk, TF, Bouchard, P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012;366(5):409–20.Google Scholar

Donnez, J, Donnez, O, Matule, D, et al. Long-term medical management of uterine fibroids with ulipristal acetate. Fertil Steril 2016;105(1):165–73.e4.CrossRef Google Scholar PubMed

Fauser, BC, Donnez, J, Bouchard, P, et al. Safety after extended repeated use of ulipristal acetate for uterine fibroids. PLoS One 2017;12(3):e0173523.Google Scholar

Shen, Q, Hua, Y, Jiang, W, et al. Effects of mifepristone on uterine leiomyoma in premenopausal women: a meta-analysis. Fertil Steril 2013;100(6):1722–6.e1–10.CrossRef Google Scholar PubMed

Luo, X, Yin, P, Coon, V JS et al. The selective progesterone receptor modulator CDB4124 inhibits proliferation and induces apoptosis in uterine leiomyoma cells. Fertil Steril 2010;93(8):2668–73.Google Scholar

Wilkens, J, Chwalisz, K, Han, C, et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J Clin Endocrinol Metab 2008;93(12):4664–71.CrossRef Google Scholar PubMed

Schutt, B, Kaiser, A, Schultze-Mosgau, MH, et al. Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women. Hum Reprod 2016;31(8):1703–12.Google Scholar

Lethaby, A, Vollenhoven, B, Sowter, M. Efficacy of preoperative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review. BJOG 2002;109(10):1097–108.Google Scholar

Lee, MJ, Yun, BS, Seong, SJ, et al. Uterine fibroid shrinkage after short-term use of selective progesterone receptor modulator or gonadotropin-releasing hormone agonist. Obstet Gynecol Sci 2017;60(1):69–73.Google Scholar

Moroni, R, Vieira, CS, Ferriani, RA, Candido-dos-Reis, FJ, Brito, LGO. Pharmacological treatment of uterine fibroids. Ann Med Health Sci Res 2014;4(Suppl 3):S185–92.CrossRef Google Scholar PubMed

Struthers, RS, Nicholls, AJ, Grundy, J, et al. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. J Clin Endocrinol Metab 2009;94(2):545–51.CrossRef Google Scholar PubMed

Archer, DF, Stewart, EA, Jain, RI, et al. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study. Fertil Steril 2017;108(1):152–60.e4.Google Scholar

MacLean, DB, Shi, H, Faessel, HM, Saad, F. Medical castration using the investigational oral GnRH antagonist TAK-385 (relugolix): phase 1 study in healthy males. J Clin Endocrinol Metab 2015;100(12):4579–87.Google Scholar

Sumitani, H, Shozu, M, Segawa, T, et al. In situ oestrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/intracrine mechanism. Endocrinology 2000;141(10):3852–61.Google Scholar

Hadji, P, Body, JJ, Aapro, MS, et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008;19(8):1407–16.Google Scholar

Deng, L, Wu, T, Chen, XY, Xie, L, Yang, J. Selective oestrogen receptor modulators (SERMs) for uterine leiomyomas. Cochrane Database Syst Rev 2012;10:CD005287.Google Scholar